References
A. S. Avedisova, R. V. Akhankin, V. I. Akhapkina, et al., “Analysis of non-Russian studies of nootropic agents (using piracetam as an example), Ros. Psikhiat. Zh., 1, 57–63 (2001).
G. Ya. Avrutskii and A. I. Niss, Pharmacology of the Nootropes (Experimental and Clinical Studies) [in Russian], Moscow (1989), pp. 112–118.
Yu. A. Aleksandrovskii, G. M. Rudenko, G. G. Neznamov, et al., A Unified System for Evaluating the Clinical-Pharmacological Actions of Psychotropic Agents in Patients with Borderline Neuropsychiatric Disorders [in Russian], Moscow (1984).
Yu. A. Aleksandrovskii, Psychopharmacotherapy [in Russian], Moscow (2005).
A. V. Valdman and T. A. Voronina, Pharmacology of the Nootropes (Experimental and Clinical Studies). Collected Studies [in Russian], Moscow (1989).
T. A. Voronina and S. B. Seredenin, “Nootropic agents, advances and new problems,” Éksperim. Klin. Farmakol., 61, No. 4, 3–9 (1998).
S. I. Gavrilova, The Pharmacotherapy of Alzheimer's Disease [in Russian], Puls, Moscow (2003).
G. Glants, Medical and Biological Statistics [Russian translation from English], Moscow (1999).
T. A. Gudasheva, R. U. Ostrovskaya, S. S. Trofimov, et al., “Peptide analogs of piracetam as ligands of presumptive nootrope receptors,” Khim.-Farm. Zh., 11, 1322–1329 (1985).
I. V. Lamulin, Mild Cognitive Impairments. Methodological Guidelines for Doctors [in Russian], RKI Severo Press, Moscow (2004).
V. V. Zakharov and N. N. Yakhno, Memory Disorders, GEOTARMED, Moscow (2003).
Ya. B. Kalyn', Mental Health of the Population of Elderly and Aged People (A Clinical-Epidemiological Study) [in Russian], Author's Abstract of Doctoral Thesis in Medical Sciences, Moscow (2001).
G. V. Kovalev, Nootropic Substances [in Russian], Volgograd (1990).
O. S. Levin, “Diagnosis and treatment of moderate cognitive impairments in the elderly,” Zh. Nevrol. Psikhiat., 8, 42–49 (2006).
International Statistical Classification of Diseases and Health-Related Problems (ICD-10) [Russian translation], WHO, Geneva (1995).
S. N. Mosolov, Basic Psychopharmacology [in Russian], Vostok, Moscow (1996).
G. G. Neznamov, S. A. Syunyakov, I. A. Davydova, and E. S. Teleshova, “The ‘fast’ and 'slow’ components of the psychotropic actions of agents with nootropic properties,” Zh. Nevrol. Psikhiat., 100, No. 6, 33–37 (2000).
G. G. Neznamov, E. S. Teleshova, S. A. Syunyakov, et al., “Treatment of mental disorders in neurology. Clinical studies of the new peptide agent Noopept in patients with psychoorganic disorders,” Consilium Medicum (Neurology/Mental Disorders), 9, No. 2, 10–15 (2007).
R. U. Ostrovskaya, T. A. Gudasheva, T. A. Voronina, and S. B. Seredenin, “The original nootropic and neuroprotective dipeptide Noopept (GVS-111),” Éksper. Klin. Farmakol., 65, No. 5, 66–72 (2002).
S. A. Piyavskii, Numerical Decision-Taking Methods in Computerized Methods in Technical Creativity in Construction [in Russian], ASV, Moscow (1994).
Handbook of Psychiatry [in Russian], A. S. Tiganov (ed.), Meditsina, Moscow (1999), Vol. 2.
V. I. Sergienko and I. B. Bondareva, Mathematical Statistics in Clinical Trials [in Russian], Moscow (2001).
A. A. Skoromets, Neurotransmitters in Brain Aging: the Key to Understanding Memory and Attention Disorders [in Russian], Moscow (2005).
E. Arnaiz and O. Almkvist, “Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease,” Acta Neurol. Scand., 107, Supplement 179, 34–41 (2003).
D. A. Bennett, “Mild cognitive impairment,” Clin. Geriat. Med., 20, 15–25 (2004).
H. Braak, K. Del Tredici, and E. Braak, “Spectrum of pathology,” in: Mild Cognitive Impairment, R. C. Petersen (ed.), Oxford University Press (2003), pp. 149–189.
C. E. Coffey, W. E. Wilkinson, I. A. Parashos, et al., “Quantitative cerebral anatomy of the aging human brain,” Neurology, 42, 527–536 (1992).
H. C. Comijs, M. G. Dik, D. J. H. Deeg, et al., “The course of cognitive decline in older patients,” Dement. Geriat. Cogn. Dis., 17, 136–142 (2004).
E. Daly, D. Zaitchik, M. Copeland, et al., Clinical Predictors of Conversion to Alzheimer's Disease, B. Vellas et al. (eds.), Serdi Publisher, Paris (2001), Vol. 5, pp. 44–49.
W. Danysz, C. G. Parsons, H.-J. Mobius, et al., “Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease-A unified glutamatergic hypothesis on the mechanism of action,” Neurotox. Res., 2, 85–97 (2000).
D. De Wied, Neurochemical and Psychopharmacological Approaches to Cognitive Entracers, Kyoto (1995).
M. F. Folstein, S. E. Folstein, and P. R. McHugh, J. Psychiat. Res., 12, No. 3, 189–198 (1975).
C. Giurgea, “Vers une pharmacologie de l'activite integrative du cerveau. Tentative du concept nootrop en psychopharmacologie,” Actual Pharmacol., 25, 115–157 (1972).
T. Gudasheva, T. Voronina, R. Ostrovskaya, et al., “Synthesis and antiamnestic activity of a series of N-acylprolyl-containing dipeptides,” Eur. J. Med. Chem., 31, 151–157 (1996).
J. W. Jacobs, M. R. Bernhard, F. Delgado, and J. J. Strain, Ann. Int. Med., 86, 40–46 (1977).
D. S. Knopman, B. F. Boeve, and R. C. Petersen, “Essentials of the proper diagnoses of mild cognitive impairment, dementia, and major subtypes of dementia,” Mayo Clinic Proc., 78, 1290–1308 (2003).
National Institute of Mental Health, 12-CGI. Clinical Global Impression, W. Guyo (ed.), ECDEU Assessment Manual for Psychopharmacology, Rockville, Maryland (1976), 217–222.
R. Ostrovskaya et al., Anxiolytic Activity of Nootropic Dipeptide Noopept, Nova Sci. Publ. (2006), Vol. 10, pp. 1–10.
K. Palmer, L. Backman, B. Winblad, and L. Fratiglioni, “Detection of Alzheimer's disease and dementia in the preclinical phase: population based cohort study,” Brit. Med. J., 326, 245–249 (2003).
R. S. Petersen, G. E. Smith, S. C. Waring, et al., “Mild cognitive impairment: clinical characterization and outcome,” Arch. Neurol., 56, 303–308 (1999).
R. S. Petersen, “Mild cognitive impairment: transition from aging to Alzheimer's disease,” in: Advances of Etiology, Pathogenesis, and Therapeutics, K. Igbal et al. (eds.), Wiley, Chichester, etc. (2001), pp. 140–151.
B. Reisberg, S. H. Ferris, et al., Psychopharm. Bull., 19, 47–50 (1983).
K. Ritchie, S. Artero, and J. Touchon, “Classification criteria for mild cognitive impairment. A population-based validation study,” Neurology, 56, 37–42 (2001).
S. Seredenin, T. Voronina, T. Gudasheva, R. Ostrovskaya, et al., “Biologically active N-acylprolyldipeptides having antiamnestic, antihypoxic, and anorexigenic effects,” US Patent No. 5439930 (1995).
Author information
Authors and Affiliations
Additional information
Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 108, No. 3, pp. 33–42, March, 2008.
Rights and permissions
About this article
Cite this article
Neznamov, G.G., Teleshova, E.S. Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin. Neurosci Behav Physi 39, 311–321 (2009). https://doi.org/10.1007/s11055-009-9128-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11055-009-9128-4